Pancreatic Cancer Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type {Diagnostic Imaging Tests (CT scan, MRI, Ultrasound, Others), Biopsy, Blood Tests, Liver Function Tests, Others}, By Cancer Type (Exocrine, Adenocarcinoma, Squamous Cell Carcinoma, Colloid Carcinoma, Others), By End User (Hospitals & Clinics, Diagnostic Centers, Others), By Region and Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 3.01 Billion
CAGR (2026-2031)	7.29%
Fastest Growing Segment	Blood Tests
Largest Market	North America
Market Size (2031)	USD 4.59 Billion

Market Overview

The Global Pancreatic Cancer Diagnostics Market is projected to grow from USD 3.01 Billion in 2025 to USD 4.59 Billion by 2031 at a 7.29% CAGR. The Global Pancreatic Cancer Diagnostics Market comprises various medical technologies and tests utilized for the detection, staging, and monitoring of pancreatic cancer, including advanced imaging, biomarker assays, molecular diagnostics, and biopsy techniques. This market's expansion is driven by the escalating global incidence of pancreatic cancer, its high mortality rate, and inherent difficulties in early diagnosis. The increasing demand for advanced diagnostic technologies, such as non-invasive liquid biopsies and AI-powered imaging for more accurate disease identification, further propels market growth.

The growing disease burden highlights a critical need for diagnostic solutions. According to the American Cancer Society, an estimated 67,440 individuals will be diagnosed with pancreatic cancer in the United States in 2025, underscoring the necessity for improved detection methods. A significant impediment to market expansion remains the substantial cost and limited accessibility of advanced diagnostic technologies across various regions, often delaying optimal patient care.

Key Market Drivers

The growing global incidence of pancreatic cancer is a primary driver fueling expansion in the diagnostics market. This rising disease burden necessitates more widespread and effective diagnostic tools to identify the cancer earlier and improve patient outcomes. Pancreatic cancer remains a highly lethal malignancy, with late diagnosis significantly contributing to its poor prognosis. The urgency to detect this cancer at more treatable stages is amplified by its steadily increasing occurrence. According to the Lustgarten Foundation, in their report citing the American Cancer Society's Cancer Facts & Figures 2026 in January 2026, incidence has increased by about 1% per year since the 1990s, indicating a persistent upward trend. This trend underscores the continuous demand for enhanced diagnostic capabilities globally.

Advancements in diagnostic technologies and techniques also critically influence the Global Pancreatic Cancer Diagnostics Market. Innovations in areas such as liquid biopsies, advanced imaging, and artificial intelligence are transforming the landscape of early detection and accurate staging. These technological strides aim to overcome the inherent challenges of pancreatic cancer diagnosis by offering less invasive and more precise methods. According to BioSpace, in August 2025, NVIDIA partnered with 12 worldwide institutions to create an overall pancreatic CT dataset, aiming to develop early detection rates for the disease. This collaborative effort highlights the strategic investments in leveraging advanced technology for diagnostic improvement. Furthermore, according to AIM ImmunoTech, in April 2026, a rights offering in early March 2026 targeted approximately $1.8 million to support its work in metastatic pancreatic cancer. Such funding initiatives contribute to the overall growth and innovation within the diagnostics sector.

Download Free Sample Report

Key Market Challenges

The substantial cost and limited accessibility of advanced diagnostic technologies present a significant impediment to the expansion of the Global Pancreatic Cancer Diagnostics Market. High capital expenditure required for acquiring and maintaining advanced imaging equipment, complex biomarker assays, and molecular diagnostic platforms restricts their widespread adoption, particularly in healthcare systems with budget constraints or in developing regions. This financial barrier limits the installed base of advanced diagnostic tools and subsequently the volume of tests performed, thereby slowing market growth.

Furthermore, restricted access to these specialized technologies across various geographical areas directly impacts patient care by delaying optimal diagnosis. According to the American Cancer Society's Cancer Facts & Figures 2026 report, as highlighted by the Lustgarten Foundation, only 17% of patients are diagnosed at a localized stage where treatment is most effective. This low rate of early detection demonstrates a critical gap in utilizing advanced diagnostic solutions, which could otherwise identify the disease at earlier, more manageable stages. The lack of equitable access, compounded by the significant expenses associated with these tests, directly curtails the potential market penetration and overall growth of advanced pancreatic cancer diagnostics.

Key Market Trends

Advanced molecular profiling and next-generation sequencing are significantly influencing the global pancreatic cancer diagnostics market by enabling granular understanding of tumor biology. This detailed genomic analysis identifies specific mutations and molecular alterations crucial for guiding targeted therapies and personalized treatment strategies. Increasing availability and reimbursement pathways for these advanced tests are broadening adoption among oncologists. For instance, according to Illumina, in January 2026, its FDA-approved TruSight Oncology Comprehensive test received reimbursement approval from the Centers for Medicare and Medicaid Services at $2,989.55 per test, establishing a clear pathway for Medicare beneficiaries. This financial support fosters greater integration of comprehensive genomic profiling into routine clinical practice, driving market growth.

The emergence of multi-cancer early detection platforms is another pivotal trend, aiming to identify pancreatic cancer alongside other malignancies in asymptomatic individuals. These innovative blood-based tests represent a paradigm shift from reactive diagnosis to proactive screening, offering potential to detect pancreatic cancer at earlier, more treatable stages. By screening broader populations, these platforms expand the addressable market for pancreatic cancer diagnostics, prompting further confirmatory testing. According to Guardant Health, in June 2025, its Shield multi-cancer detection test demonstrated 68% sensitivity for pancreatic cancer in a clinical validation study and was granted Breakthrough Device designation by the U.S. Food and Drug Administration. Such advancements are critical for improving early detection rates for a cancer historically known for late-stage diagnosis.

Segmental Insights

The Blood Tests segment is the fastest-growing within the Global Pancreatic Cancer Diagnostics Market, primarily driven by the urgent clinical need for early detection of this aggressive cancer. This rapid expansion stems from significant advancements in biomarker discovery, including the identification of more specific protein and genetic markers, which enhance test accuracy and sensitivity for early-stage disease. The non-invasive nature and ease of administration of blood tests make them increasingly favored for initial screening and monitoring therapeutic response. Ongoing research and validation efforts by institutions like the National Institutes of Health's Pancreatic Cancer Detection Consortium further accelerate the adoption of novel liquid biopsy techniques in clinical practice.

Regional Insights

North America leads the global pancreatic cancer diagnostics market, primarily driven by its sophisticated healthcare infrastructure and significant investments in medical research and development. The region benefits from a robust regulatory environment, including the Food and Drug Administration (FDA), which streamlines the approval and integration of innovative diagnostic technologies. This facilitates early patient access to advanced screening and diagnostic tools. Additionally, heightened awareness regarding early cancer detection, coupled with the strong presence of key market players and a high incidence of pancreatic cancer, collectively fortifies North America's dominant position in the market.

Recent Developments

• In January 2026, National Institutes of Health (NIH)-supported investigators developed a new blood test designed to identify pancreatic ductal adenocarcinoma, one of the deadliest forms of cancer. This breakthrough research, conducted by scientists at the University of Pennsylvania Perelman School of Medicine and Mayo Clinic, identified novel blood markers, aminopeptidase N (ANPEP) and polymeric immunoglobin receptor (PIGR). When combined with existing markers, this four-marker panel successfully distinguished pancreatic cancer cases from non-cases with high accuracy, particularly in early stages. This diagnostic advancement could significantly improve survival rates by enabling earlier detection.
• In January 2026, RenovoRx, Inc. presented new clinical data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. While the primary focus of the TIGeR-PaC trial is on therapy for locally advanced pancreatic cancer, the pharmacokinetic and pharmacodynamic data provided diagnostic insights. The study observed a direct correlation between increased levels of an inactive gemcitabine metabolite and reduced CA 19-9, a biomarker commonly used to assess chemotherapy response. This strengthens the understanding of diagnostic markers in treatment monitoring.
• In December 2025, Singlera Genomics, in collaboration with Breakthrough Genomics and the University of Pittsburgh, announced a research initiative to advance the preclinical evaluation of the BT-Reveal™ Early Pancreatic Cancer Test. This advanced blood test utilizes Singlera's mTitan platform to screen circulating cell-free DNA for cancer signals before symptoms typically manifest. The collaboration aims to study the efficacy and impact of pancreatic cancer screening in high-risk populations, moving towards a larger-scale FDA longitudinal study. This diagnostic development represents a crucial step in enabling earlier detection and treatment of pancreatic cancer.
• In December 2025, Acurion partnered with the Pancreatic Cancer Action Network (PanCAN) to integrate its AI-enhanced platform, OncoGaze™, with PanCAN's SPARK health data integration platform. This collaboration focused on applying OncoGaze™ to digitized pathology images, aiming to uncover patterns that better explain disease progression and treatment response. The initiative leverages artificial intelligence in diagnostic analysis, representing an advancement in molecular understanding of pancreatic cancer. This effort is designed to accelerate data-driven research, providing valuable insights for the pancreatic cancer diagnostics market and potentially guiding future therapeutic decisions.

Key Market Players

• Siemens Healthineers AG
• Myriad Genetics, Inc.
• Pfizer, Inc
• Novartis AG
• AstraZeneca plc
• Immunovia AB
• Laboratory Corporation of America Holdings
• Abbott Laboratories
• Agilent Technologies, Inc.
• Thermo Fisher Scientific Inc.

By Test Type {Diagnostic Imaging Tests	By Cancer Type	By End User	By Region
CT scan MRI Ultrasound Others	Exocrine Adenocarcinoma Squamous Cell Carcinoma Colloid Carcinoma Others	Hospitals & Clinics Diagnostic Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Pancreatic Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Pancreatic Cancer Diagnostics Market, By Test Type {Diagnostic Imaging Tests:

• CT scan
• MRI
• Ultrasound
• Others

• Pancreatic Cancer Diagnostics Market, By Cancer Type:

• Exocrine
• Adenocarcinoma
• Squamous Cell Carcinoma
• Colloid Carcinoma
• Others

• Pancreatic Cancer Diagnostics Market, By End User:

• Hospitals & Clinics
• Diagnostic Centers
• Others

• Pancreatic Cancer Diagnostics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE